Viridian Therapeutics Stock (NASDAQ:VRDN)
Previous Close
$19.21
52W Range
$11.40 - $27.20
50D Avg
$19.57
200D Avg
$17.47
Market Cap
$1.54B
Avg Vol (3M)
$1.39M
Beta
1.11
Div Yield
-
VRDN Company Profile
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
VRDN Performance
Peer Comparison
| Ticker | Company |
|---|---|
| RVMD | Revolution Medicines, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| KURA | Kura Oncology, Inc. |
| ACLX | Arcellx, Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| SNDX | Syndax Pharmaceuticals, Inc. |
| GPCR | Structure Therapeutics Inc. |
| BPMC | Blueprint Medicines Corporation |
| NUVL | Nuvalent, Inc. |
| REPL | Replimune Group, Inc. |
| MRUS | Merus N.V. |
| CYTK | Cytokinetics, Incorporated |
| ETNB | 89bio, Inc. |
| PTGX | Protagonist Therapeutics, Inc. |
| INZY | Inozyme Pharma, Inc. |
| PCVX | Vaxcyte, Inc. |